Cullen Capital Management LLC Buys 545,406 Shares of Pfizer Inc. (NYSE:PFE)

Cullen Capital Management LLC grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 12.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,774,380 shares of the biopharmaceutical company's stock after acquiring an additional 545,406 shares during the period. Cullen Capital Management LLC owned 0.08% of Pfizer worth $126,664,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of PFE. Norges Bank bought a new position in Pfizer in the 4th quarter worth approximately $2,328,986,000. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Pfizer during the fourth quarter worth $274,694,000. Massachusetts Financial Services Co. MA lifted its stake in shares of Pfizer by 7.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. Finally, Fisher Asset Management LLC boosted its holdings in Pfizer by 79.5% in the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company's stock valued at $295,760,000 after acquiring an additional 4,938,209 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Pfizer Stock Down 5.4 %

PFE traded down $1.30 during trading on Friday, reaching $22.99. The company had a trading volume of 79,829,399 shares, compared to its average volume of 39,460,357. The company has a market cap of $130.39 billion, a P/E ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12 month low of $22.95 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business's fifty day moving average price is $25.87 and its 200 day moving average price is $26.72.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.10 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Bank of America reissued a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $31.92.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.